Literature DB >> 1827835

Factors affecting the normal and branched-chain acyl moieties of teicoplanin components produced by Actinoplanes teichomyceticus.

A Borghi1, D Edwards, L F Zerilli, G C Lancini.   

Abstract

Teicoplanin, a glycopeptide antibiotic produced by Actinoplanes teichomyceticus, comprises five main components, denoted T-A2-1 to T-A2-5, differing in the structure of their acyl side chain, which is linear in T-A2-1 and T-A2-3 and branched in the other components. Production of T-A2-1, characterized by a linear C10:1 acyl moiety, is entirely dependent on the presence of linoleate in the fermentation medium. Addition to the medium of oleic acid esters at 2 g l-1 increases the yields of T-A2-3, characterized by a linear C10:0 acyl chain, about threefold. The antibiotic linear side chains thus appear to originate from C18 unsaturated acid by beta-oxidation degradation. The percentage of T-A2-2, T-A2-4 and T-A2-5, bearing the iso-C10:0, anteiso-C11:0 and iso-C11:0 acyl moieties, respectively, is strongly influenced by the presence in the medium of the amino acids known to be precursors of branched-chain fatty acids. Thus, valine increases the production of T-A2-2 whereas isoleucine or leucine increase the relative yields of T-A2-4 or T-A2-5, respectively. Analysis of the total cell lipids upon addition of the same amino acid shows corresponding increases in the proportion of the iso-C16:0, iso-C15:0 or anteiso-C17:0. A mutant A. teichomyceticus strain, which produces a novel teicoplanin with a linear C9:0 chain, differs from the wild strain in the presence of the linear C17:1 acid in its lipids.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1827835     DOI: 10.1099/00221287-137-3-587

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  8 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

Review 2.  How nature morphs peptide scaffolds into antibiotics.

Authors:  Elizabeth M Nolan; Christopher T Walsh
Journal:  Chembiochem       Date:  2009-01-05       Impact factor: 3.164

Review 3.  Teicoplanin biosynthesis: unraveling the interplay of structural, regulatory, and resistance genes.

Authors:  Oleksandr Yushchuk; Bohdan Ostash; Andrew W Truman; Flavia Marinelli; Victor Fedorenko
Journal:  Appl Microbiol Biotechnol       Date:  2020-02-19       Impact factor: 5.560

4.  Factors influencing cell fatty acid composition and A40926 antibiotic complex production in Nonomuraea sp. ATCC 39727.

Authors:  Srdjan Jovetic; Marina Feroggio; Flavia Marinelli; Giancarlo Lancini
Journal:  J Ind Microbiol Biotechnol       Date:  2008-07-24       Impact factor: 3.346

5.  Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin.

Authors:  Carlo Taurino; Luca Frattini; Giorgia Letizia Marcone; Luciano Gastaldo; Flavia Marinelli
Journal:  Microb Cell Fact       Date:  2011-10-18       Impact factor: 5.328

Review 6.  Recent Advances in the Development of Semisynthetic Glycopeptide Antibiotics: 2014-2022.

Authors:  Emma van Groesen; Paolo Innocenti; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2022-07-27       Impact factor: 5.578

Review 7.  Old and New Glycopeptide Antibiotics: Action and Resistance.

Authors:  Elisa Binda; Flavia Marinelli; Giorgia Letizia Marcone
Journal:  Antibiotics (Basel)       Date:  2014-11-04

8.  Strain Improvement and Strain Maintenance Revisited. The Use of Actinoplanes teichomyceticus ATCC 31121 Protoplasts in the Identification of Candidates for Enhanced Teicoplanin Production.

Authors:  Luca Mellere; Adriana Bava; Carmine Capozzoli; Paola Branduardi; Francesca Berini; Fabrizio Beltrametti
Journal:  Antibiotics (Basel)       Date:  2021-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.